Список литературы

2658-6533

Research Results in Biomedicine

2658-6533

10.18413/2313-8955-2016-2-4-24-29

866

Medicine (miscellaneous)

PECULIARITIES OF CALCIUM AND PHOSPHORUS METABOLISM OF THE PATIENTS UNDERGOING MEDICAL TREATMENT WITH PROGRAMMED HEMODIALYSIS

Golovin

Andrey I.

Golovin

Andrey I.

Efremova

Olga A.

Efremova

Olga A.

efremova@bsu.edu.ru

Khodykina

Julia E.

Khodykina

Julia E.

2016

2400

In recent years, a steadily increasing number of patients undergoing treatment with programmed hemodialysis has been registered worldwide. The tendency is connected with a constant growth in the number of cases of chronic kidney failure, including its terminal stage, alongside with a greater availability of the hemodialysis. It has been found out that the changes in the key parameters of calcium and phosphorus metabolism increase the risk of developing bone and heart-vascular pathology as well as secondary hyperparathyroidism for the dialysis patients. The article presents the results of the statistical evaluation of the calcium and phosphorus metabolism in the patients subjugated to the programmed hemodialysis.

calcium and phosphorus metabolismhemodialysischronic kidney failure

Список литературы

1. Bikbov B.T., Tomilina N.A. Replacement therapy in patients with chronic renal failure and methods of peritoneal dialysis kidney transplantation in the Russian Federation in 1998-2011 years. (Report to the Russian Register of renal replacement therapy. Part Two). Nephrology and Dialysis. Vol. 16. № 2. 2014. Pp. 198-199.

2. Bikbov B.T., Tomilina N.A. The composition of patients and quality of care indicators in the substitution treatment of terminal chronic renal failure in the Russian Federation in 1998-2013 years. (Report according to renal replacement therapy register Russian Dialysis Society. Part Two) Nephrology and Dialysis, 2016. Vol. 18. №2. Pp. 123-125.

3. Bondar I.A, Klimontov V.V.,  Koroleva  E.A. Alfakaltsidol in correction of a phosphorus-calcium exchange at patients with a chronic illness of kidneys//The Russian Medical Journal. 2008. N. 7. 463p

4. Gavrilenkov P.V. Features of calcium and phosphorus metabolism in patients with chronic renal failure treated with chronic hemodialysis. Abstract of the PhD thesis in Medicine. St. Petersburg, 2002. P.3

5. Ermolenko V.M., Chronic renal failure. Nephrology: national leadership. Edited by. ON. Mukhina. M.: GEOTAR Media. 2009. Pp. 579-629

6. Zemchenkov A.Y., Gerasimchuk R.P. Activators of vitamin D receptors and vascular calcification (a review). Nephrology. Dialysis. 2009. 4 (11). Pp.276-292

7. Kolomiets M.V., Bilchenko A.V. Xanthine metabolism in the progression of chronic heart failure: features of disorders in patients with concomitant chronic kidney disease. Research results. Series "Medicine and Pharmacy". Vol. 2. № 1(7). Pp. 17-23.

8. Milovanova L.Y., Milovanov Y.S., Kozlovskaya L.V. Imbalances of calcium-phosphorus metabolism in chronic kidney disease stages III-V. Clinical Nephrology. 2011. №1. Pp. 58-68

9. New opportunities in the treatment of secondary hyperparathyroidism in patients on hemodialysis therapy in combination with small doses of cinacalcet and the active metabolite of vitamin D / Shutov E.V., Lashutin S.V., Lyuosev V.S., Ryabinskaya G.V., Gorelova E. A., Levankovskaya E.I. Clinical Nephrology. 2011. № 5. Pp. 41-46.

10. Sviridova M.S., Efremova O.A., Kamyshnikova L.A. The prevalence of chronic kidney disease stage I-III in the Belgorod region.  Scientific statements Belgorod State University. Series: Medicine. Pharmacy. 2013. Vol. 21. № 4. (147). Pp. 182-186.

11. Modern aspects of diagnostics and hyperparathyroidism treatment in patients with the chronic illness of kidneys / Efremova O.A., Malikova A.A., Kamyshnikova L.A., Bolkhovitina O.A. Scientific Bulletin of Belgorod State University. Series: Medicine. Pharmacy. 2015. № 22. (219). Pp. 12-17.

12. Chuprasov V.B. Long term hemodialysis. SPb.: Foliant, 2001. 312 p.

13. Block G.A., Hulbert-Shearon T.E., Levin N.W., Port F.K. Association of serum phosphorus and calcium x phosphorus product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 1998. 31. Pp. 607-617

14. Craver L., Marco M.P., Martinez I. et al. Mineral metabolism parameters throughout chronic kidney disease stages 1–5-achievement of K/DOQI target ranges. Nephrol. Dial. Transplant. 2007. 22. Pp. 1171-1176.

15. Danese M., Belozeroff V., Smirnakis K. et al. Consistent control of mineral and bone disorder in incident hemodialysis patients. Clin. J. Am. Soc. Nephrol. 2008. 3. Pp.  1423-1429.

16. Floege J., Kim J., Ireland E. et al. Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol. Dial. Transplant. 2010. 10. Pp. 1-8.

17. Horl W. H. The clinical consequences of secondary hyperparathyroidism: focus on clinical outcomes. Nephrol. Dial. Transplant. 2004. Vol. 19, Suppl. 5. P. 2-8.

18. Kalantar-Zadeh K., Kuwae N., Regidor D. et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006. 70. Pp. 771-780.

19. National Kidney Foundation. K/DOQI clinical practice guidelines: bone metabolism and disease in chronic kidney disease. Am. J. Kidney Dis. 2003. 42 (Suppl 4). Pp.  1-201.

20. Tan AU Jr., Levine B.S., Mazess R.B. et al. Effective suppression of parathyroid hormone by 1 alpha-hydroxy-vitamin D2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism. Kidney Int. 1997. 51. Pp.  317-323.

21. Wang L., Jerosch-Herold M., Jacobs J. et al. Coronary Artery Calcification and Myocardial Perfusion in Asymptomatic Adults: The MESA (Multi-Ethnic Study of Atherosclerosis). J. Am. Coll. Cardiol. 2006. 48. Pp. 1018-1026.